From Podium To Practice – Breast Cancer ESMO Part 7
In this segment, Dr. Wassim Mchayleh and Dr. Sara Tolaney discuss how extensive crossover in ASCENT-03 may obscure potential overall survival (OS) differences in first-line metastatic triple-negative breast cancer (mTNBC). They review early OS trends, high crossover rates exceeding 80%, and the clinical challenge of attrition between first- and second-line therapy—where up to 25% of patients never receive subsequent treatment. The conversation contrasts these findings with TROPION-Breast02, explaining why datopotamab deruxtecan (dato-DXd) did not include crossover due to the absence of prior OS-proven data. They also examine notable differences in objective response rate (ORR), PFS, and patient-risk profiles across trials. Sponsored By Gilead.